The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | MRD sequencing test approved for MM in the US
Nikhil Munshi
• 5 Oct 2018
Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the prospects for measurable residual disease (MRD) testing following the recent FDA approval of a deep sequencing-based technique for MRD detection in multiple myeloma (MM). This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
